Positive new data presented for Fiasp in children and adolescents

For children and adolescents (1 to <18 years old) living with type 1 diabetes, Fiasp (an ultra-fast acting formulation of insulin aspart) could be an option to better manage their blood sugar levels, when used as part of a multiple daily injection routine (also known as a basal-bolus regimen).

This is the view of Fiasp’s marketer, Danish diabetes care giant Novo Nordisk (NOV: N), whose shares were lifted 2.08% to 272.85 Danish kroner by early afternoon trading.

New data presented today at the 44th Annual Conference of the International Society for Pediatric and Adolescent Diabetes (ISPAD), now taking place in Hyderabad, India, showed that the study population receiving Fiasp achieved superior reductions in overall blood sugar levels (HbA1c), compared to the group on conventional insulin aspart, when both treatments were dosed at mealtime (estimated treatment difference (ETD) -0.17%). In addition, significantly lower overall post-meal blood sugar levels (1-hour after the meal) were achieved with Fiasp compared to conventional insulin aspart.